Safety of loncastuximab tesirine‐lpyl in diffuse large B‐cell lymphoma with severe hepatic dysfunction

Abstract

AbstractDiffuse large B‐cell lymphoma (DLBCL) is an aggressive subtype of non‐Hodgkin lymphoma with a high rate of disease relapse despite the achievement of clinical responses to frontline chemoimmunotherapy treatments. Loncastuximab tesirine‐lpyl is a novel anti‐CD19 antibody conjugated to an alkylating pyrrolobenzodiazepine agent (SG3199), and it has been approved for relapsed/refractory (r/r) DLBCL. Baseline moderate to severe hepatic impairment has an unclear impact on the safety of loncastuximab tesirine‐lpyl, and there is a lack of clear guidance on dose adjustment from the manufacturer. The authors present two cases of r/r DLBCL safely treated with full‐dose loncastuximab tesirine‐lpyl in the setting of severe hepatic dysfunction.